Table 1. Patient characteristics, clinical response, and toxicity.
| Patient | Age/sex | Disease sites | Prior therapy | No. of cycles received* | Response (mos.) | Toxicity (grade III/IV) |
|---|---|---|---|---|---|---|
| 1 | 52/M | Lung | I, S | 2 | PR (15+) | Enterocolitis; dermatitis |
| 2 | 40/F | Supraclavicular lymph node | C, I, S | 1 | NR | Dermatitis; vitiligo† |
| 3 | 39/M | Lung, mediastinum, subcutaneous | S | 6 | NR (mixed) | |
| 4 | 55/F | Skin, subcutaneous | I, S | 1 | NR | Pulmonary infiltrates† |
| 5 | 67/M | Liver, retroperitoneum, subcutaneous | C, I, R, S | 4 | NR | ANA+† |
| 6 | 59/M | Lung, subcutaneous | I, S | 4 | NR | Vitiligo† |
| 7 | 48/M | Lung, brain, adrenal, subcutaneous | I, S | 2 | NR | |
| 8 | 48/M | Lung, liver, adrenal, mesentery, subcutaneous | C, I, S | 2 | NR | |
| 9 | 53/M | Mediastinum, mesentery, skin | I, R, S | 2 | NR | Colitis |
| 10 | 62/M | Lung, hilum | C, I, S | 2 | NR (mixed) | |
| 11 | 54/M | Lung, brain, subcutaneous | C, S | 5 | CR (12+) | Hypophysitis |
| 12 | 43/M | Subdiaphragm, muscle, subcutaneous | I, S | 3 | NR | Hepatitis; ANA+† |
| 13 | 49/F | Lung, subcutaneous | C, I, S | 4 | CR (11+) | Dermatitis |
| 14 | 63/M | Lung, pelvic lymph node | S | 4 | NR |
ANA, antinuclear Ab; C, chemotherapy; CR, complete response; F, female; I, immunotherapy; M, male; NR, no response; PR, partial response; R, radiotherapy; S, surgery
*
One treatment cycle consists of one infusion of anti-CTLA-4 Ab and one vaccination with gp 100:209-217(210M) and gp 100:280-288(288V) peptides
†
Grade I/II toxicity